Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Mikael Lee Rinne, M.D.,Ph.D.

Co-Author

This page shows the publications co-authored by Mikael Rinne and Patrick Wen.
Connection Strength

2.873
  1. Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for temozolomide. Oncology (Williston Park). 2015 Apr; 29(4):265, 275.
    View in: PubMed
    Score: 0.634
  2. Central nervous system complications of cancer therapy. J Support Oncol. 2012 Jul-Aug; 10(4):133-41.
    View in: PubMed
    Score: 0.518
  3. Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma. JCO Precis Oncol. 2019; 3.
    View in: PubMed
    Score: 0.209
  4. Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. J Clin Oncol. 2019 03 20; 37(9):741-750.
    View in: PubMed
    Score: 0.207
  5. PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma. Neurology. 2018 10 02; 91(14):e1355-e1359.
    View in: PubMed
    Score: 0.201
  6. A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy. Neuro Oncol. 2016 06; 18(6):849-54.
    View in: PubMed
    Score: 0.169
  7. Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. Neuro Oncol. 2015 Jun; 17(6):862-7.
    View in: PubMed
    Score: 0.156
  8. Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas. J Neurooncol. 2015 Jan; 121(2):297-302.
    View in: PubMed
    Score: 0.154
  9. Phase ii trial of the phosphatidyinositol-3 kinase (pi3k) inhibitor buparlisib (bkm120) in recurrent glioblastoma conducted by the ivy foundation early phase clinical trials consortium. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii47.
    View in: PubMed
    Score: 0.151
  10. Update on bevacizumab and other angiogenesis inhibitors for brain cancer. Expert Opin Emerg Drugs. 2013 Jun; 18(2):137-53.
    View in: PubMed
    Score: 0.139
  11. Activity of PD-1 blockade with Nivolumab among patients with recurrent atypical/anaplastic meningioma: Phase II trial results. Neuro Oncol. 2021 May 20.
    View in: PubMed
    Score: 0.061
  12. A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma. Neuro Oncol. 2016 Feb; 18(2):269-74.
    View in: PubMed
    Score: 0.041
  13. Extent of resection and overall survival for patients with atypical and malignant meningioma. Cancer. 2015 Dec 15; 121(24):4376-81.
    View in: PubMed
    Score: 0.041
  14. Rapid Intraoperative Molecular Characterization of Glioma. JAMA Oncol. 2015 Aug; 1(5):662-7.
    View in: PubMed
    Score: 0.041
  15. Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. Neuro Oncol. 2015 Oct; 17(10):1344-55.
    View in: PubMed
    Score: 0.039
  16. Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma. J Neurooncol. 2015 Feb; 121(3):557-63.
    View in: PubMed
    Score: 0.039
  17. Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab. Neuro Oncol. 2014 Nov; 16(11):1523-9.
    View in: PubMed
    Score: 0.038
  18. Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma. Neuro Oncol. 2014 Nov; 16(11):1547-53.
    View in: PubMed
    Score: 0.037
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.